000			03159nam a22003495i 4500
001			76165
003			ES-MaUEC
005			20230207040212.0
007			cr nn 008mamaa
008			100301s2006 xxu| s |||| 0|eng d
020			_a9781592599158
040			_aES-MaUEC
050		4	_aRC280.B8 _bB56 2006 EB
245	0	0	_aBiomarkers in Breast Cancer : _bMolecular Diagnostics for Predicting and Monitoring Therapeutic Effect _cedited by Giampietro Gasparini, Daniel F. Hayes
260			_aTotowa, NJ _bHumana Press _c2006
300			_bonline resource
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aCancer Drug Discovery and Development
520			_aIt is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisando
650		7	_aMamas _xCáncer _0comprobar BNE19901364206 _2embne _9182522
700	1		_aGasparini, Giampietro _eeditor literario _985079 _0Local
700	1		_aHayes, Daniel F. _eeditor literario _0Local _985080
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1385/159259915X _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781592599158
907			_a.b12817831 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b17-03-17 _cm _dz _ek _feng _gxxu _h0
945			_aRC280.B8 B56 2006 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11547054 _z06-04-17
999			_c76165 _d76165 _x1